Participants in the Solicitation. Sumitovant and its directors and executive officers, Sumitomo Pharma and its directors and executive officers, and ▇▇▇▇▇▇▇ and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of Myovant common stock in respect of the proposed transaction. Information about the directors and executive officers of ▇▇▇▇▇▇▇ is set forth in the proxy statement for ▇▇▇▇▇▇▇’s 2022 Annual Meeting of Shareholders, which was filed with the SEC on July 28, 2022. Investors may obtain additional information regarding the interest of such participants by reading the proxy statement regarding the acquisition when it becomes available.
Appears in 2 contracts
Sources: Acquisition Agreement (Myovant Sciences Ltd.), Acquisition Agreement